Sinopharm stock faces a 2.95 percent interim profit drop

Published on 10/07/2026 at 03:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sinopharm stock traded at HKD 14.73 on October 2, 2026, near its HKD 14.58 yearly low. Retail pharmacy revenue rose 8.58 percent in first-half 2026.

Sinopharm, CNE100000FN7, Illustration mit AI erstellt.

Sinopharm stock (ISIN CNE100000FN7) was last at HKD 14.73 on the Hong Kong Stock Exchange on October 2, 2026, 0.87 percent below the previous close. The latest interim report shows a mixed first-half picture, with retail pharmacy growth offsetting pressure on the core distribution business.

Profit falls in first half

According to FilingReader on September 22, 2026, Sinopharm reported operating income of RMB 282,799.61 million for the six months ended June 30, 2026, down 1.13 percent year over year. Net profit declined 2.95 percent to RMB 5,179.80 million, while profit attributable to the parent company fell 1.79 percent to RMB 3,403.77 million.

Basic earnings per share decreased 1.80 percent to RMB 1.09 for the same period, according to Futu. The distribution businesses remained the main drag, with pharmaceutical distribution revenue down 1.39 percent and medical device distribution revenue down 0.35 percent.

Retail pharmacy offsets pressure

The strongest operating counterweight came from retail pharmacies. Revenue in that segment rose 8.58 percent to RMB 18,635.02 million in the first half of 2026, while the overall expense ratio improved to 4.11 percent from a year earlier, according to FilingReader.

The contrast matters for investors because Sinopharm combines a high-volume distribution operation with a faster-growing retail channel. The first-half figures show that retail expansion is meaningful, but its RMB 18,635.02 million revenue base remains smaller than pharmaceutical distribution revenue of RMB 215,496.05 million.

Analysts see upside to HKD 21.13

According to Investing.com, the consensus covers 15 analysts and carries a Buy rating. The average 12-month target is HKD 21.13, with the highest target at HKD 27.77985729 and the lowest at HKD 17.06047491; the average target lies 43.45 percent above the October 2 price of HKD 14.73.

UOB Kay Hian listed Sinopharm at Hold with a HKD 17.00 target in its China healthcare report dated October 2, 2026, according to UOB Kay Hian. Its target stands 15.40 percent above the October 2 reference price, showing a more cautious view than the broader consensus.

Stock stays near yearly low

Sinopharm stock was last at HKD 14.73 on October 2, 2026, compared with a 52-week range of HKD 14.58 to HKD 17.92. The price was 0.87 percent below the previous close, while market capitalization stood at HKD 53.0 billion on the same date.